Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial - Concepedia

Concepedia

Publication | Closed Access

Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial

326

Citations

17

References

2017

Year

Karen E. Anderson, David Stamler, Mat D. Davis, Stewart A. Factor, Robert A. Hauser, Jouko Isojärvi, L. Fredrik Jarskog, Joohi Jimenez‐Shahed, Rajeev Kumar, Joseph P. McEvoy,

The Lancet Psychiatry

PsychiatryRehabilitationPharmacotherapyInvoluntary MovementsTardive DyskinesiaMedicineMovement Disorders

References

	Year	Citations

Page 1